Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation
Post Views: 181 Insilico Medicine, a global clinical-stage biotechnology company specializing in the applications of end-to-end artificial intelligence (AI) for drug discovery and development, today announced that the company has nominated preclinical candidates (PCC) for ISM012-077 and ISM012-042 for the treatment of anemia of chronic kidney disease (CKD) and inflammatory bowel disease (IBD), respectively.ISM012-077 and…